Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2016
At a glance
- Drugs Basiliximab (Primary) ; Ciclosporin
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 26 Oct 2012 Planned end date changed from 1 Sep 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 15 May 2012 Actual patient number 17 added as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.